Mandate

Vinge advises GTCR in relation to the recommended public offer to the shareholders in Cision

February 14, 2014

Vinge advises Blue Canyon Holdings AB, controlled by GTCR Investment X AIV Ltd., in relation to the public offer to the shareholders in Cision AB (publ). The shares in Cision are admitted to trading on NASDAQ OMX Stockholm. The Board of Directors of Cision recommends Cision’s shareholders to accept the Offer, and the four largest shareholders, representing 43.3 per cent of the shares, have undertaken to accept the offer. GTCR offers SEK 52 in cash per share and the total offer value for all shares in Cision amounts to approximately SEK 775 million.

Cision is a leading provider of cloud-based PR software, services and tools for the media, marketing and public relations industries. Founded in 1980, GTCR is a leading US-based private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare, and Information Services & Technology Industries. Since its inception, GTCR has invested more than USD 10 billion in over 200 companies.

Peter Bäärnhielm, Dain Nevonen and Jo-Anna Nordström assist in connection with the offer. Joacim Rydergård and others assist in connection with due diligence. Mikael Ståhl and Albert Wållgren advise on financing issues. Christina Kokko is client responsible partner. 

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024